Investor Presentaiton slide image

Investor Presentaiton

Russia business sustaining uncertain macro economic conditions REVENUES (Rouble mn) +9% 10,005 10,115 8,891 8,041 STRATEGIC FOCUS 6,817 • Focus on portfolio augmentation and productivity improvement • Continue to Scale-up the OTC business • Establish Biosimilar business with launch of Reditux FY12 FY13 FY14 FY15 FY16 • Established strong presence in Pain Management, G.I. & Anti-Infectives therapies Top 5 brands rank #1 in their respective segments & 12 brands in the top 3
View entire presentation